A Study to Evaluate ALN-6222 in Participants With Obesity
Enrolling
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Trial at a Glance
- Trial ID
- ALN-6222-001
- Condition
- Obesity
- Drug/Treatment
- Placebo, ALN-6222
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 88 participants
- Trial dates
- 2026-06-04 - 2027-12-14
For more information:NCT07624071
Who can participate?
AGE
18 to 65 Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
No
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
